Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
24.4 EUR | -1.61% | -1.61% | +2.52% |
04-04 | 1000mercis: RNPG increased by half in 2023 | CF |
04-01 | Healthcare firm PACS Group eyes up to $3.25 bln valuation in US IPO | RE |
Valuation
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capitalization 1 | 70.88 | 59.23 | 48.41 | 47.53 | 59.22 | 53.61 |
Enterprise Value (EV) 1 | 71.49 | 63.19 | 45.4 | 43.35 | 57.32 | 74.07 |
P/E ratio | 16.5 x | 24.7 x | -7.12 x | 45.8 x | 26.7 x | 16.2 x |
Yield | 1.22% | - | - | - | 37.2% | - |
Capitalization / Revenue | 1.01 x | 0.82 x | 0.81 x | 0.68 x | 0.75 x | 0.68 x |
EV / Revenue | 1.01 x | 0.88 x | 0.76 x | 0.62 x | 0.73 x | 0.94 x |
EV / EBITDA | 8.28 x | 9.27 x | -25.8 x | 9.17 x | 12.9 x | 13.4 x |
EV / FCF | -29.5 x | -25.4 x | 4.45 x | 5.51 x | -22.4 x | 61.9 x |
FCF Yield | -3.38% | -3.94% | 22.5% | 18.1% | -4.46% | 1.62% |
Price to Book | 1.37 x | 1.22 x | 1.22 x | 1.44 x | 1.69 x | 3.3 x |
Nbr of stocks (in thousands) | 2,881 | 2,632 | 2,554 | 2,160 | 2,161 | 2,162 |
Reference price 2 | 24.60 | 22.50 | 18.95 | 22.00 | 27.40 | 24.80 |
Announcement Date | 30/04/19 | 30/04/20 | 30/04/21 | 14/04/22 | 13/04/23 | 30/04/24 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net sales 1 | 70.52 | 72.21 | 60.04 | 70.21 | 78.92 | 78.78 |
EBITDA 1 | 8.635 | 6.817 | -1.761 | 4.729 | 4.439 | 5.522 |
EBIT 1 | 5.317 | 2.207 | -6.31 | 0.481 | 1.798 | 3.473 |
Operating Margin | 7.54% | 3.06% | -10.51% | 0.69% | 2.28% | 4.41% |
Earnings before Tax (EBT) 1 | 5.432 | 2.504 | -7.08 | 0.879 | 1.922 | 3.13 |
Net income 1 | 4.239 | 2.502 | -6.796 | 1.044 | 2.22 | 3.317 |
Net margin | 6.01% | 3.47% | -11.32% | 1.49% | 2.81% | 4.21% |
EPS 2 | 1.490 | 0.9100 | -2.661 | 0.4800 | 1.027 | 1.530 |
Free Cash Flow 1 | -2.419 | -2.493 | 10.21 | 7.86 | -2.554 | 1.197 |
FCF margin | -3.43% | -3.45% | 17.01% | 11.19% | -3.24% | 1.52% |
FCF Conversion (EBITDA) | - | - | - | 166.21% | - | 21.68% |
FCF Conversion (Net income) | - | - | - | 752.86% | - | 36.09% |
Dividend per Share 2 | 0.3000 | - | - | - | 10.20 | - |
Announcement Date | 30/04/19 | 30/04/20 | 30/04/21 | 14/04/22 | 13/04/23 | 30/04/24 |
Balance Sheet Analysis
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net Debt 1 | 0.6 | 3.97 | - | - | - | 20.5 |
Net Cash position 1 | - | - | 3 | 4.18 | 1.9 | - |
Leverage (Debt/EBITDA) | 0.0699 x | 0.5819 x | - | - | - | 3.706 x |
Free Cash Flow 1 | -2.42 | -2.49 | 10.2 | 7.86 | -2.55 | 1.2 |
ROE (net income / shareholders' equity) | 8.2% | 5.2% | -15.5% | 2.87% | 6.52% | 12.9% |
ROA (Net income/ Total Assets) | 3.4% | 1.47% | -4.21% | 0.34% | 1.36% | 2.49% |
Assets 1 | 124.7 | 170.1 | 161.5 | 311.1 | 162.9 | 133.4 |
Book Value Per Share 2 | 18.00 | 18.40 | 15.50 | 15.30 | 16.20 | 7.510 |
Cash Flow per Share 2 | 6.970 | 5.250 | 7.780 | 8.970 | 7.190 | 10.10 |
Capex 1 | 3.48 | 3.55 | 2.25 | 1 | 1.05 | - |
Capex / Sales | 4.93% | 4.92% | 3.74% | 1.42% | 1.33% | - |
Announcement Date | 30/04/19 | 30/04/20 | 30/04/21 | 14/04/22 | 13/04/23 | 30/04/24 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+2.76% | 17.41B | |
-1.58% | 12.36B | |
-13.17% | 10.7B | |
-1.22% | 10.22B | |
+8.74% | 4.57B | |
-3.31% | 3.29B | |
+9.24% | 3.05B | |
-28.95% | 3.02B | |
+7.40% | 2.85B |
- Stock Market
- Equities
- ALMIL Stock
- 2PL Stock
- Financials 1000mercis